ÂÜÀòÂÒÂ×

Yonglei Shang has extensive experience in the biotechnology industry. Yonglei began their career as a Research Associate at UT Southwestern Medical Center at Dallas in 2003. Yonglei then moved to Genentech in 2004, where they held the roles of Sr. Scientific Researcher at Antibody Engineering, Sr. Research Associate, and Research Associate. In 2018, they joined Amberstone Biosciences as SVP, Head of Discovery and Early Development, and later became VP, Head of Antibody Therapeutics, overseeing therapeutic antibody/Biologics research and early development with a focus on cancer immunotherapy.

Yonglei Shang holds an MD from Jining Medical College in China, an MS in Medical Sciences from Capital Medical University in China, and an MS in Molecular Medicine from UT Health San Antonio.